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In this issue of Critical Care, Dempﬂ  e and colleagues [1] 
present an original double-blind study assessing the 
biological eﬀ  ect of the combination of enoxaparin and 
Drotrecogin alpha (activated) (DAA) (recombinant 
human activated protein C) for the treatment of acute 
sub  massive pulmonary embolism (PE). Th  e authors 
demon  strate that DAA infusion accelerates the control of 
coagulation activation in patients with a D-dimer level 
higher than 4 mg/L.
Th  is phase II exploratory study sponsored by Eli Lilly 
and Company (Indianapolis, IN, USA) [2] is of special 
interest because the use of thrombolytic therapy in 
patients with submassive PE is a matter of signiﬁ  cant and 
ongoing debate [3,4]. Low-molecular-weight heparins 
(LMWHs) still represent the gold standard for the 
treatment of venous thromboembolism, as they have 
proven to be very eﬀ  ective and to have a high eﬃ   cacy/
safety ratio [5]. Nevertheless, evidence suggests that 
thrombolytic agents may rapidly dissolve blood clots and 
might reduce the death rate associated with PE. However, 
there are concerns about the possible risk of adverse 
eﬀ  ects of these agents, such as life-threatening hemor-
rhage. Th  erefore, another antithrombotic drug could be 
an attractive alternative.
DAA, a vitamin K-dependent protein, is a potent anti-
coagulant agent that inhibits activated coagulation 
factors V and VIII (Va and VIIIa) [6]. Th   is mechanism is 
responsible for a signiﬁ   cant reduction in thrombin 
generation. It also promotes ﬁ   brinolysis by inhibiting 
ﬁ   brino  lytic inhibitors such as plasminogen activator 
inhibitor-1 and thrombin-activatable ﬁ  brinolysis inhibi  tor. 
Th   e global resultant eﬀ  ect of DAA on coagulation is more 
than complex. Dhainaut and colleagues [7] have 
demonstrated that this compound could be beneﬁ  cial in 
overt and nonovert disseminated intravascular coagu  la-
tion patients while partially controlling the activation of 
the system. Moreover, DAA has been used in managing 
acute myocardial infarction patients after thrombolysis 
[8]. As an activation of the coagulation system with a 
high level of thrombin generation is often observed in 
(nonseptic) PE patients, combining DAA with an LMWH 
could be understood as a very interesting hypothesis in 
this regard, even if the sum of the two parts is not as great 
as the whole.
Dempﬂ   e and colleagues have compared increasing   
doses of DAA for a short duration of infusion (12 hours) 
with placebo in enoxaparin-treated patients. Up to now, 
little has been known about the endogenous plasma level 
of activated protein C in (nonseptic) PE patients. 
Interestingly, the endogenous activated protein C levels 
were elevated in the DAA-treated group but not in the 
control group. Th  is unexpected ﬁ   nding represents the 
pivotal data of this study, creating the potential for 
further developments in the ﬁ  eld.
Unfortunately, the road to improve our understanding 
of drugs is not always straightforward. Some hurdles can 
slow down the development of our projects. Sometimes, 
physicians use shortcuts to save time, forgetting that 
pharmacology follows very strict rules. It seems that no 
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Combining therapeutic doses of low-molecular-
weight heparins and increasing doses of recombinant 
activated protein C – Drotrecogin alpha (activated), 
or DAA – is of theoretical interest with regard to 
the control of coagulation activation. The study by 
Dempfl  e and colleagues presents new data showing 
that endogenous activated protein C levels do not 
increase in nonseptic patients with pulmonary 
embolism. However, the results of the addition of these 
two treatments are puzzling, leaving unresolved the 
questionable clinical relevance of this combination and 
the possible increase in bleeding risk.
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before the start of the study by Dempﬂ  e and colleagues. 
Combining a potent anticoagulant (LMWH) with another 
one (DAA) should have been tested, at least, in healthy 
volunteers.
Furthermore, if LMWHs have already been given 
concomitantly with therapeutic doses of DAA in the past 
[9-11], the doses were only prophylactic, and, to our 
knowledge, no therapeutic doses have ever been com-
bined with DAA in nonseptic patients, and this is because 
the bleeding risk of these patients is much diﬀ  erent than 
that of hypercoagulable septic patients. As already 
mentioned, DAA develops an anticoagulant activity. In 
several pivotal DAA trials in sepsis, some major bleeding 
episodes have been reported to be related to this 
anticoagulant eﬀ  ect [10,11]. Moreover, in daily clinical 
practice, the induced-bleeding risk of DAA was reported 
to be much higher than that of the control trials [12]. In 
the study by Dumpﬂ  e and colleagues, which is actually 
registered as a safety study [2], the observed results are a 
little bit disappointing, leaving unresolved the potentially 
increased bleeding risk. Th  e authors state that DAA 
accelerates the control of coagulation activation in a 
subgroup of patients with high levels of intravascular 
ﬁ  brin. Is there any clinical need for that? No signiﬁ  cant 
diﬀ  erence is observed in echocardiographic data between 
the treated group and the control group. Finally, as one 
patient in the DAA group developed an intracranial 
hemorrhage (which is fairly uncommon in enoxaparin-
treated patients), the question of the clinical beneﬁ  t of 
such a combination has to be raised, notwithstanding the 
low power of this study to detect an increase in major 
bleeding. Eventually, the debate remains very interesting. 
DAA is a fascinating compound, and its never-ending 
story is complex!
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